Pruritus Therapeutic Market Growth, Industry Latest Trends, Size, Key Drivers, Top Players And Forecast To 2033

The new report published by The Business Research Company, titled "Pruritus Therapeutic Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the pruritus therapeutic market size has grown strongly in recent years. It will grow from $13.1 billion in 2023 to $14.2 billion in 2024 at a compound annual growth rate (CAGR) of 8.4%. The pruritus therapeutic market size is expected to see strong growth in the next few years. It will grow to $19.7 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=9925&type=smp

Rising Incidences Of Skin Disorders Propel Growth In The Pruritus Therapeutic Market
The increasing incidences of skin disorders are significantly contributing to the growth of pruritus therapeutic. Skin conditions refer to dermatologic conditions or skin disorders such as acne, eczema, skin cancer, psoriasis, and vitiligo that affect the skin. Pruritus therapeutics are used as a part of treatment for various skin diseases as most skin disorders have pruritus as a predominant symptom. For instance, in April 2022, according to the American Academy of Dermatology Association, a US-based association for dermatology, melanoma is expected to claim the lives of 7,650 people in 2022, including 5,080 males and 2,570 women. Additionally, in January 2023, according to the American Cancer Society, a US-based voluntary organization, In the United States, a projected 97,610 new melanoma cases will be diagnosed in 2023, with about 58,120 in men and 39,490 in women. Therefore, the increasing incidences of skin disorders will drive the pruritus therapeutic market.

Pioneering Product Developments Drive Momentum In The Pruritus Therapeutic Market
Product innovation is the key trend gaining popularity in the pruritus therapeutic market. Major companies operating in the pruritus therapeutic market are focusing on developing innovative medications and treatments for pruritus and related conditions. For instance, in August 2022, Maruho Co., Ltd. a Japan-based pharmaceutical company, launched the anti-IL-31 receptor, a humanized monoclonal antibody Mitchga Subcutaneous Injection 60 mg Syringes for the treatment of itching associated with atopic dermatitis. It is the first antibody drug that inhibits IL-31 signalling. IL-31 is a neuroimmune cytokine2 linked to pruritus and skin inflammation in the progression of atopic dermatitis3,4. The substance inhibits IL-31 binding to its receptor and inhibits itch and skin inflammation associated with atopic dermatitis.

The pruritus therapeutic market covered in this report is segmented -

1) By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors, Others Types
2) By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types
3) By Application: External Use, Oral, Injection
4) By End Use: Hospitals, Clinics, Other Uses

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=9925&type=discount

Major companies operating in the pruritus therapeutic market report are Allergan plc, Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company, Galderma Laboratories LP, GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Abbott Laboratories, Almirall SA, Eisai Co. Ltd., Glenmark Pharmaceuticals Ltd., Ipca Laboratories Ltd., Lupin Chemicals Ltd., Cara Therapeutics Inc., EPI Health LLC, AbbVie Inc., Actavis plc, Albireo Pharma Inc., Amgen Inc., Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals Inc., Evelo Bioscience Inc., Huapont Life Sciences Co. Ltd., J&J Services Inc., LEO Pharma AS, MC2 Therapeutics Ltd., Mylan NV, Novan Inc., Ocera Therapeutics Inc., Trevi Therapeutics Inc., UCB SA, Viatris Inc., Teva Pharmaceutical Industries Ltd. .

Contents of the report:
1. Executive Summary
2. Pruritus Therapeutic Market Report Structure
3. Pruritus Therapeutic Market Trends And Strategies
4. Pruritus Therapeutic Market - Macro Economic Scenario
5. Pruritus Therapeutic Market Size And Growth
…..
27. Pruritus Therapeutic Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.